دانلود رایگان مقاله انگلیسی سرطان سینه همزیست و ازدیاد پلاکت های خون - هینداوی 2018

قیمت خرید این محصول

رایگان

دانلود مقاله انگلیسی سفارش ترجمه این مقاله

عنوان فارسی

سرطان سینه همزیست و ازدیاد پلاکت های خون: چگونه چالش های درمانی را نشان دادیم

عنوان انگلیسی

Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges

صفحات مقاله فارسی

صفحات مقاله انگلیسی

سال انتشار

2018

نشریه

هینداوی - Hindawi

فرمت مقاله انگلیسی

PDF

نوع نگارش

Case report

رفرنس

دارد

کد محصول

E10452

رشته های مرتبط با این مقاله

پزشکی

گرایش های مرتبط با این مقاله

خون و آنکولوژی

مجله

گزارشات موردی در هماتولوژی - Case Reports in Hematology

دانشگاه

Department of Internal Medicine - University of Florida College of Medicine - USA

doi یا شناسه دیجیتال

https://doi.org/10.1155/2018/2080185

برای سفارش ترجمه این مقاله با کیفیت عالی و در کوتاه ترین زمان ممکن توسط مترجمین مجرب سایت ایران عرضه؛ روی دکمه سبز رنگ کلیک نمایید.

چکیده

Essential thrombocythemia (ET) occurring with breast cancer is uncommon; the therapeutic approach varies and poses a challenge. A 65-year-old female presented to us after being diagnosed with hormone positive, HER2-negative infiltrating ductal carcinoma. She had a platelet count of 600 thou/cu mm. Her JAK2 mutation was positive. Bone marrow biopsy showed increased megakaryocytes. She was diagnosed with ETin the setting of breast cancer. She underwent breast conservation surgery after which aspirin was resumed. Anticipating thrombocytopenia during chemotherapy and given the absence of data combining hydroxyurea with standard chemotherapy used for breast cancer, we felt it prudent to delay cytoreductive therapy for her ET until after completion of breast cancer treatment. Her average platelet count during chemotherapy was 480 thou/cu mm with the lowest being 377 thou/cu mm. Her platelet count remained at goal between 300 and 350 thou/cu mm after four months of hydroxyurea.

نتیجه گیری

Conclusion

(i) Physicians are faced with several therapeutic challenges when ET coexists with solid tumours.

(ii) )ese should be managed on an individual basis.

(iii) One should take into consideration the risk of thrombosis and the therapeutic approach for solid tumours in the management of these patients.

(iv) Extended VTE prophylaxis during chemotherapy may be needed in select cases.

(v) ET and breast cancer both have favourable outcomes, and therefore, treatment for one should not preclude treatment for the other.

برچسب‌ها: دانلود رایگان مقالات انگلیسی پزشکی، دانلود رایگان مقالات isi